Skip to main content

Cancer epigenetics

Cancer epigenetics: from laboratory studies and clinical trials to precision medicine





Epigenetic dysregulation is a common feature of a myriad of human diseases, particularly cancer. Defining the epigenetic defects associated with malignant tumors has become a focus of cancer research resulting in the gradual elucidation of cancer cell epigenetic regulation. In fact, most stages of tumor progression, including tumorigenesis, promotion, progression, and recurrence are accompanied by epigenetic alterations, some of which can be reversed by epigenetic drugs. The main objective of epigenetic therapy in the era of personalized precision medicine is to detect cancer biomarkers to improve risk assessment, diagnosis, and targeted treatment interventions. Rapid technological advancements streamlining the characterization of molecular epigenetic changes associated with cancers have propelled epigenetic drug research and development. This review summarizes the main mechanisms of epigenetic dysregulation and discusses past and present examples of epigenetic inhibitors in cancer diagnosis and treatment, with an emphasis on the development of epigenetic enzyme inhibitors or drugs. In the final part, the prospect of precise diagnosis and treatment is considered based on a better understanding of epigenetic abnormalities in cancer.
Facts

Epigenetic regulatory mechanisms involve cancer biology, especially DNA methylation, histone acetylation, and miRNAs.

The expression of tumor-related genes is closely related to the epigenetic regulatory process of tumors.

DNMTi, HDACis, BETis and other epigenetic therapies are constantly being updated and used in the clinic.

Epigenetic combination therapy is a promising direction.

Multi-omics, gene therapy, and AI are favorable transitions from epigenetic therapy to precision medicine.

Mechanisms of epigenetic dysregulation in cancer

Epigenetics is defined as a series of biological processes involving chromatin-mediated DNA template regulation, independent of changes in the original DNA sequence. Protein complexes that control epigenetic modifications (including DNA methylation and covalent histone modification) can be divided into writers, readers, and erasers. Epigenetic writers add distinct epigenetic chemical modifications to DNA or histones in the form of epigenetic markers. Readers are methyl-CpG-binding domain proteins (MBPs) that identify and interpret the specialized domains of modified proteins. Chromatin-modifying enzymes function as erasers by removing epigenetic markers. Epigenetic dysregulation, including DNA, RNA methylation defects and abnormal post-translational modification processes, is commonly associated with all cancer types.
Fig. 1: Epigenetic alterations associated with carcinogenesis.


Epigenetic alterations involve DNA methylation, histone acetylation, and miRNA regulation that have reversible effects on gene silencing and activation through epigenetic enzymes and related proteins. Writers (DNMT, HAT, and KMT) are enzymes that add acetyl (Ac) and methyl (Me) tags to histones. MBDs are readers that recognize methyl-CpG and modify histones. Erasers (DNA demethylase, HDAC, and KDM) are responsible for removing chemical groups from DNA or histones. Noncoding RNAs (miRNAs and lncRNAs) are also involved in epigenetic regulation. A DNA methylation in normal and cancer cells. The overall hypomethylation and local hypermethylation of promoter regions are characteristics of cancer cells. P: promoter region. B Methylation and demethylation of lysine or arginine in histones. Lysine can be methylated once (me1), twice (me2) or three times (me3) catalyzed by KMT. Arginine is methylated once (me1) or twice (me2) catalyzed by KMT. These processes can be reversed by KDM. C HDAC removes acetyl groups from histone lysine residues. Acetylated histones are considered “active chromatin” allowing gene transcription, whereas deacetylated histones are “non-active chromatin” associated with gene silencing. D The methylation of m6A is installed by the RNA methyltransferase complex with the catalytic subunit METTL3/METTL4 (writer) and removed by demethylases, such as FTO and ALKBH5 (eraser). m6A reader proteins (YTHDCs) can specifically bind m6A transcripts. DNMT, DNA methyltransferase; HAT, histone acetyltransferase; HDAC, histone deacetylase; KDM, lysine demethylase; KMT, lysine methyltransferase; m6A, N6-Methyladenosine. MBP, methyl-CpG-binding domain protein.

epigenetics, drugs, gene expression, histone modifications, DNA methylation, non-coding RNAs, cancer, genetic disorders, small molecules, gene therapies, CRISPR, off-target effects, tissue delivery, drug specificity, epigenome, restoration, clinical applications, molecular therapies, gene regulation, pharmacological interventions, biomarkers, therapeutic targets, precision medicine, therapeutic efficacy, drug resistance, epigenetic regulation, targeted therapies.
#epigenetics, #drugs, #geneexpression, #histonemodifications, #DNAmethylation, #noncodingRNAs, #cancer, #geneticdisorders, #smallmolecules, #genetherapies, #CRISPR, #offtargeteffects, #tissuedelivery, #drugspecificity, #epigenome, #restoration, #clinicalapplications, #moleculartherapies, #generegulation, #pharmacologicalinterventions, #biomarkers, #therapeutictargets, #precisionmedicine, #therapeuticefficacy, #drugresistance, #epigeneticregulation, #targetedtherapies.

International Conference on Genetics and Genomics of Diseases 




For Enquiries: genetics@healthcarek.com 

Get Connected Here 
--------------------------------- 
--------------------------------- 

    Comments

    Post a Comment

    Popular posts from this blog

    Genetics role in ovarian cancer

    The Medical Minute: Genetics play big role in ovarian cancer In 2024, about 19,680 women in the United States will receive a new diagnosis of ovarian cancer and 12,740 women will die from the disease, said Dr. Shaina Bruce , a gynecologic oncologist at Penn State Cancer Institute . The median age of all patients who develop ovarian cancer is 63. Historically, women at increased risk for ovarian cancer are recommended to have their fallopian tubes and ovaries removed when they have completed having children. Taking that step to protect themselves comes at a heavy price ― surgical menopause. But Bruce said medical science is catching up with ovarian cancer. Studies could lead to new methods for preventative care and the surgery needed to lower risk may be easier than it once was. Below, during Gynecologic Cancer Awareness Month, Bruce discusses the disease and why acting to reduce your risk is worth it. What’s the connection between heredity and ovarian cancer? About 25% of all cases of ...
    Post a Comment
    Read more

    X chromosome

    Gene on the X chromosome may help explain high multiple sclerosis rates in women Brain inflammation may be fueled by a gene on the X chromosome, a new study in mice suggests. And in female mice, who carry two X chromosomes, a diabetes drug called metformin may work to counteract that inflammation. If these findings bear out in later studies, they could help to unravel the long-standing mystery of why women, who have two copies of this inflammation-driving gene, are more prone to certain autoimmune diseases, particularly after menopause. A disparity between the sexes Our bodies are patrolled by immune cells that provide protection against bacteria and viruses, but sometimes, these defenses turn on us. In the autoimmune disorder multiple sclerosis (MS), for instance, the immune system attacks myelin, the fatty insulation surrounding the nerve fibers in the brain and spinal cord. This leads to symptoms such as muscle weakness and difficulty walking, as well issues with memory and thinking...
    Post a Comment
    Read more

    Multifactorial Genetic Conditions

    Multifactorial Genetic Conditions Multifactorial genetic conditions are disorders caused by the combined effects of multiple genes and environmental factors , rather than a single gene mutation . These conditions do not follow classic Mendelian inheritance patterns and instead result from complex gene–environment interactions . Factors such as lifestyle, nutrition, infections, stress, and exposure to toxins can significantly influence disease onset and severity in genetically susceptible individuals. Common examples include diabetes, cardiovascular diseases , neural tube defects, asthma, and many neuropsychiatric disorders. Understanding multifactorial inheritance is essential for risk prediction, preventive medicine, and personalized healthcare strategies. Multifactorial inheritance, polygenic traits, gene–environment interaction, complex diseases, genetic susceptibility, environmental risk factors, non-Mendelian inheritance, disease predisposition, polygenic risk score, precision ...
    Post a Comment
    Read more